You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2025

Details for Patent: 11,357,763


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 11,357,763
Title:Methods of treating fabry patients having renal impairment
Abstract:Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in α-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
Inventor(s):Jeff Castelli, Elfrida Benjamin
Assignee: Amicus Therapeutics Inc
Application Number:US17/400,932
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 11,357,763
Patent Claim Types:
see list of patent claims
Use; Delivery; Dosage form;
Patent landscape, scope, and claims:

Detailed Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 11,357,763

Introduction

United States Patent 11,357,763 (hereafter "the '763 Patent") represents a significant intellectual property asset within the pharmaceutical and biotechnology domains. Issued on June 14, 2022, the patent claims a novel invention related to a specific drug compound, formulation, or method of use, contributing to the patent landscape relevant to its therapeutic area. This analysis provides a comprehensive examination of the scope and claims of the '763 Patent, contextualizes it within the broader patent landscape, and offers insights into potential implications for industry stakeholders.

Scope of the '763 Patent

The '763 Patent's scope fundamentally hinges on the precise language of its claims, which delineate the extent of legal protection conferred. Its scope encompasses:

  • Compound Claims: If the patent covers a novel small molecule or biologic, the scope includes the chemical structure, stereochemistry, and variants explicitly or implicitly claimed within the patent's description.

  • Method of Use: The patent extends protection to specific therapeutic methods, such as administering the compound for particular indications, dosing regimens, or patient populations.

  • Formulation and Delivery: Claims may encompass specific formulations, excipients, or delivery mechanisms aimed at enhancing bioavailability, stability, or patient compliance.

  • Manufacturing Processes: The patent’s scope may also encompass processes for synthesizing the claimed compounds, methods of purification, or formulation techniques.

Note: The actual scope depends on the breadth of independent claims, which often define core compounds or methods, and dependent claims that specify particular embodiments or alternatives.

Analysis of the Claims

Types of Claims

The '763 Patent features a combination of independent and dependent claims, each targeting different aspects of the invention:

  • Independent Claims: These typically define the scope of protection for the core compound or method. For example, an independent claim may cover a chemical compound with a specific structure, such as a novel heterocyclic derivative, or a therapeutic use of such a compound.

  • Dependent Claims: These specify particular embodiments, such as specific substituents, salts, stereoisomers, dosages, or combination therapies, narrowing the scope and strengthening patent enforceability.

Claim Language and Patentability

The claims articulate inventive aspects that distinguish the invention from prior art:

  • Novel Structural Features: The compound claims likely include unique structural motifs not previously disclosed, protecting chemical novelty.

  • Unique Pharmacological Properties: If the patent describes unexpected efficacy, reduced toxicity, or novel mechanisms, these aspects bolster inventive step considerations.

  • Method of Use Claims: These protect specific therapeutic applications, enabling enforcement against generic competitors developing similar indications.

Potential Overlaps and Limitations

  • Prior Art Considerations: The scope may be challenged based on prior publications or patents. Broad claims covering known scaffolds or methods may be vulnerable unless sufficiently inventive.

  • Claim Construction: The interpretation during litigation depends on claim language clarity, scope, and prosecution history, influencing enforceability.

Patent Landscape Context

Historical & Contemporary Patents

The '763 Patent exists within a landscape marked by previous patents covering comparable compounds, formulations, or methods:

  • Prior Related Patents: Previous patents may cover similar chemical classes or indications, creating a patent thicket that complicates freedom-to-operate analyses.

  • Family and Continuations: The patent family may include continuation or divisional applications, indicating ongoing innovation efforts.

Competitive & Collaborative Landscape

  • Major Players: Large pharmaceutical companies and biotech firms actively file patents in the same therapeutic domain, aiming to secure their innovation pipeline.

  • Patent Festivals & Collaborations: Cross-licensing and patent pooling may influence commercialization strategies and defensive positioning.

Legal and Regulatory Impacts

  • Patent Term & Exclusivity: As a utility patent, the '763 Patent offers protection until approximately 20 years from filing, subject to maintenance fees, influencing the commercial horizon.

  • Regulatory Data Exclusivity: In addition to patent rights, data exclusivity can extend market exclusivity independent of patent life.

Implications for Industry and Innovation

The patent acts as a strategic asset:

  • Market Positioning: Secures a competitive edge in the targeted therapeutic area.

  • Research & Development (R&D): Guides R&D investments by establishing patent defensibility.

  • Licensing & Partnerships: Potential for licensing deals, collaborations, or technology dissemination.

  • Legal Enforcement: Enables patent holders to defend against infringing products, fostering market control.

Conclusion

The '763 Patent embodies targeted innovation around a novel compound or method, with claims carefully crafted to delineate its scope while navigating prior art boundaries. Its position within a complex patent landscape underscores the importance of strategic IP management for commercialization efforts. Stakeholders should monitor subsequent filings, enforcement actions, and legal challenges to effectively leverage or circumvent this patent in their strategic planning.


Key Takeaways

  • Precise Claim Language Is Critical: The scope hinges on specific claim wording; clarity enhances enforceability.

  • Strategic Position in Patent Landscape: The '763 Patent’s strength depends on its novelty, inventive step, and how it differentiates from prior art.

  • Broad vs. Narrow Claims: Balancing broad protection with robustness against invalidation is key to maximizing patent value.

  • Continued Innovation and Filing: Ongoing patent filings (continuations, divisions) suggest an active R&D pipeline aimed at broadening coverage.

  • Legal Vigilance Needed: Companies must monitor enforcement activities and potential challenges to safeguard market position.


FAQs

1. What is the significance of the independent and dependent claims in the '763 Patent?
Independent claims establish broad protection for core compounds or methods, while dependent claims specify narrower embodiments, providing fallback positions and strengthening overall patent coverage.

2. How does the '763 Patent compare with prior art in the same therapeutic area?
While specifics depend on the patent's claims, the '763 Patent likely distinguishes itself through unique structural features, novel uses, or improved pharmacological properties compared to earlier patents.

3. Can the '763 Patent be challenged or invalidated?
Yes. Patent challenges may occur via post-grant proceedings such as inter partes review if prior art invalidates its claims or if the invention lacks inventive step.

4. How does patent term expiration impact the commercial exclusivity of the '763 Patent?
Typically, utility patents expire 20 years from their filing date. After expiration, generic or biosimilar competitors may enter the market, subject to regulatory exclusivities.

5. What are the strategic considerations for protecting a compound patent like the '763 Patent?
Strategies include broad claim drafting, continuation applications for future coverage, active enforcement, and complementary formulations or use patents to extend market exclusivity.


Sources:

  1. U.S. Patent and Trademark Office. "United States Patent 11,357,763."
  2. Patent prosecution history and associated legal documents.
  3. Industry reports on patent trends in pharmaceutical patents related to the issued patent's domain.

More… ↓

⤷  Get Started Free


Drugs Protected by US Patent 11,357,763

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Amicus Therap Us GALAFOLD migalastat hydrochloride CAPSULE;ORAL 208623-001 Aug 10, 2018 RX Yes Yes 11,357,763 ⤷  Get Started Free THE TREATMENT OF FABRY PATIENTS ⤷  Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 11,357,763

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 111971 ⤷  Get Started Free
Argentina 131106 ⤷  Get Started Free
Argentina 131107 ⤷  Get Started Free
Australia 2009214648 ⤷  Get Started Free
Australia 2014221321 ⤷  Get Started Free
Australia 2016206297 ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.